Cancer micrometastasis and tumour dormancy

Tumour dormancy and clinical implications in breast cancer

The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence of relapse. The regulation of the switch from clinical dormancy to cancer regrowth in locoregional a...

Mathematical Modelling of Tumour Dormancy

Many tumours undergo periods in which they apparently do not grow but remain at a roughly constant size for extended periods. This is termed tumour dormancy. The mechanisms responsible for dormancy include failure to develop an internal blood supply, individual tumour cells exiting the cell cycle and a balance between the tumour and the immune response to it. Tumour dormancy is of considerable ...

Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.

Metastasis to the bone is most frequently observed in advanced cases of breast and prostate cancer. The latent development of overt metastatic lesions is associated with debilitating skeletal morbidity and eventual patient mortality. Secondary tumours in bone are derived from disseminated tumour cells (DTCs) that enter into a state of cellular dormancy. The dormant state confers resistance to c...

Genetic determinants of lung cancer micrometastasis.

Prognostic significance of VEGF- C in predicting micrometastasis and isolated tumour cells in N0 oralsqua